BioPharmSignal logoBioPharmSignal

Biotech News

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

Gyre Therapeutics (GYRE)Gyre TherapeuticsEarnings

Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to delayed Etorel® (Nintedanib) rollout and government procurement-related uncertainty

Related news

GYREGyre Therapeutics2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

KYTXKyverna Therapeutics2026-08-11 20:02 EST

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

VERAVera Therapeutics2026-08-10 20:05 EST

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

ACRSAclaris Therapeutics2026-08-06 10:59 EST

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

CUECue Biopharma Inc2026-08-14 20:05 EST

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

View all latest news

Gyre Therapeutics

Fibrosis and Inflammation Franchise Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China. Its small-molecule portfolio is centered on organ fibrosis and inflammatory diseases. Commercial Products in China Gyre Pharmaceuticals commercializes ETUARY, a pirfenidone therapy for idiopathic...

Recent company news

GYREGyre Therapeutics2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

GYREGyre Therapeutics2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

GYREGyre Therapeutics2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

GYREGyre Therapeutics2026-05-07 10:00 EST

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

GYREGyre Therapeutics2026-05-04 12:48 EST

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Stock data

Close
6.91 USD
Market cap
539.48M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States